Halozyme Therapeutics Q3 2026 Results: Net Income $247M, Up 41.0% YoY
Halozyme Therapeutics reported strong growth for the third quarter of 2026, with total revenues increasing to $493.0 million compared to $354.3 million in the prior year, driven primarily by higher royalty and product sales. Net income rose to $247.0 million, while the company significantly restructured its debt through the issuance of 2033 Convertible Notes and the repayment of 2027 and 2028 notes.
- Key figure
- Net income $247M · +41.0% YoY